Partnering Hall Speakers Agenda Overview WSGR website

Audio/video recordings are available for certain sessions. Please click on the Click here to play audio icon or Click here to play audio icon next to the panel titles.

2017 Conference Agenda

Click here for print version

Thursday June 1, 2017
Sharon Heights Golf and Country Club
2900 Sand Hill Road
Menlo Park, CA

6:00 – 9:00 p.m.

Dinner Interview
Meet Michael DeMane, chairman of Nevro, a company that he took public in late 2014 at a $425 million valuation and quickly grew to over a billion dollars in value in seven short months. But Nevro is just the latest in an amazing list of accomplishments that include a decade of service at Medtronic with jobs of increasing responsibility, ending with the position of Chief Operating Officer. Join us for dinner as David Cassak interviews this extraordinarily accomplished executive.


David Cassak, The MedTech Strategist


Michael DeMane, Nevro

Friday June 2, 2017

Palace Hotel
2 New Montgomery Street
San Francisco, CA

7:00 – 8:00 a.m.

Conference Registration and Continental Breakfast

8:00 – 8:10 a.m.

Welcome – Casey McGlynn, Wilson Sonsini Goodrich & Rosati Click here to play audio

8:10 – 9:10 a.m.

New Models for Medtech Investing Click here to play audio
Getting a new medical device company funded is more difficult today. An ever-shrinking pool of investors interested in early-stage life sciences investing, more stringent capital requirements due to prolonged regulatory and reimbursement timelines, and the need for true sales traction to garner the attention of potential corporate acquirers have all become hallmarks of the current financing environment. How are investors adapting their financing strategies and business models to accommodate these realities and positioning themselves for long-term success? Join a panel of Medtech investors as they discuss their approaches to investing in these changing times.


Donna Petkanics, Wilson Sonsini Goodrich & Rosati


Andrew ElBardissi, Deerfield Capital


Eric Milledge, Endeavor Vision SA


Leighton Read, Brandon Capital Partners  


Valeska Schroeder, KCK Group  

9:10 – 9:30 a.m.


9:30 – 10:30 a.m.

Breakout Session 1

Pacific Rim Deals with U.S. Medtech Click here to play audio
Join a panel of experienced CEOs who have completed collaborations, financings, and mergers of their businesses with companies and investors throughout Asia. Learn how these transactions are structured and the factors that draw U.S. entrepreneurs to Asia and Asian investors, as well as corporate partners and acquirers to the U.S.


Elton Satusky, Wilson Sonsini Goodrich & Rosati


Yue-Teh Jang, Medeon Biodesign, Inc.


Kewen Jin, Serica Partners 


Trevor Moody, M.H. Carnegie & Company


Norman Weldon, Partisan Management Group, Inc.

Big Medtech's Evolving Business Development Strategies
The Medtech consolidators have a challenge—they need to introduce important new products to grow their businesses, but internal innovation is both expensive and unpredictable. As a result, they are increasingly looking externally to fill their pipelines. Companies that develop these products are well positioned to be rewarded, but they need to understand what the consolidators are looking for. Increasingly, they are turning to novel deal structures that can benefit both buyer and seller. Join a panel of business development executives as they explore these issues.


Martin Waters, Wilson Sonsini Goodrich & Rosati


Edward Andrle, LivaNova PLC


Evan Norton, Abbott Ventures, Inc.  


Daniel Sheehan, Medtronic  


Gwen Watanabe, Teleflex Inc.

IP Value – A Corporate and Investor Perspective
This panel will discuss the role of IP in forming, funding, and selling companies. Panelists will also discuss the importance of IP from an investor perspective, what investors look for, and how they evaluate opportunities. Additional topics to be addressed include due diligence during funding and acquisitions, how to protect inventions, and when to license.


James Heslin, Wilson Sonsini Goodrich & Rosati


David Hovda, Simplify Medical


Beverly Huss, Qool Therapeutics


Jeffie Kopczynski, Medtronic


John Shimmick, Wilson Sonsini Goodrich & Rosati

10:30 – 10:50 a.m.


10:50 – 11:50 a.m.

Breakout Session 2

Funding Strategies for Entrepreneurs
Finding capital today is difficult, no matter the stage of the company. This panel of entrepreneurs and CEOs will share their experiences in the search for capital. Learn about the methods and strategies these Medtech leaders used to secure the capital they needed to move their projects forward.


Scott Murano, Wilson Sonsini Goodrich & Rosati


Daniel Burnett, TheraNova LLC


Duke Rohlen, Spirox, Inc.  


Fred Toney, Launchpad Digital Health  


Jay Watkins, Curation Capital  

Make America Great Again – Insights from Washington
President Trump and the 115th Congress have already detailed an extremely busy 2017, including numerous healthcare and tax reform proposals that will impact our industry. Join a discussion of the key Medtech policy issues being debated on Capitol Hill, including the Medtech industry’s need for adequate product reimbursement, a more reasonable and predictable approval process, and a host of other issues.


Mark Leahey, Medical Device Manufacturers Association (MDMA)


Andrew Cleeland, Fogarty Institute for Innovation (FII)


Mark Deem, The Foundry


Richard "Rick" Packer, Asahi Kasei Corporation/ZOLL Medical Corporation

University Licensing Strategies Click here to play audio
This session will feature a discussion between a university licensing executive and a licensing attorney representing the founders of a start-up as they move through the process of negotiating a license to university IP. Come learn about each of the key provisions in the license and its varying level of importance to each party. In addition, review a mock term sheet to uncover the issues under discussion as the founders and university licensing executives work to reach a deal satisfactory to both sides.


Farah Gerdes, Wilson Sonsini Goodrich & Rosati


Anne Kopf-Sill, Stanford University


Sara Nakashima, Stanford University

11:50 a.m. – 12:10 p.m.


12:10 – 1:10 p.m.

Breakout Session 3

Structuring Strategic Collaborations Click here to play audio
This panel will explore the world of Medtech Strategic Collaborations. Learn from the CEO panelists the process from first meeting to signed contract. Hear about the various structures that these transactions can take. Understand what brought each party to the bargaining table and what each hoped to gain. Find out how long these transactions take to complete from the initial meeting to execution of the definitive agreement. Hear about the key bargaining issues and how differences are narrowed to allow the transaction to proceed and eventually close.


Casey McGlynn, Wilson Sonsini Goodrich & Rosati


Octavian Florescu, Xip


Uday Kumar, Element Science


Reza Naima, ReThink Medical

Making the Case for Value Click here to play audio
The Medtech industry is being asked to show value as providers take on more risk with quality and cost metrics in new payment models. With the push to show value, multiple organizations have developed approaches for measuring and determining what value means, including HTA bodies, payers, and patient groups. AdvaMed has developed a new framework to assess the value of medical technologies and diagnostics in a broad, patient-centric approach. This panel will introduce the AdvaMed Value Framework, address the perspective of private payers in assessing value, and describe how companies are leveraging it to communicate value to stakeholders. Companies are also using the Value Framework to make internal business decisions that allow for more efficient use of capital, and during discussions with investors to assist in valuations at each milestone during the commercialization process.


Donald May, AdvaMed


Maneesh Arora, Exact Sciences Corporation


Jeff Farkas, Medtronic


Jo Carol Hiatt, Kaiser Permanente

Clinical Trials - Avoiding Major Pitfalls Click here to play audio
In the United States, about 10 percent of all 510(k) applications require clinical data to support clearance. Virtually all PMA applications must be supported by clinical data. In Europe, clinical data is generally required for both Class II devices and implantable devices. For small device companies running their first study, the process is expensive, daunting, and uncertain. Join us for this panel and hear U.S. and European experts discuss some of the major regulatory pitfalls that companies must avoid when generating clinical data to support U.S. and European regulatory approvals.


David Hoffmeister, Wilson Sonsini Goodrich & Rosati


Todd Brinton, Stanford University


Sarah Sorrel, Medpass International

1:10 – 2:20 p.m.

Lunch Interview, ForSight Labs

ForSight Labs, LLC is an ophthalmic incubator established in 2005 by renowned ophthalmologist and retinal surgeon Eugene de Juan, Jr., M.D. in collaboration with The Foundry to create one of the first field focused incubators….to identify important new opportunities in ophthalmology, to innovate to address those opportunities, and to incubate the resulting companies.

Over the past ten years, ForSight Labs has started six VISION companies, which collectively raised over $150M in capital - Transcend Medical, Inc. (Acquired by ALCON), ForSight Newco II, Inc. (Acquired by QLT), NEXIS Vision, Inc. (Out-Licensed), ForSight VISION4, Inc. (Acquired by ROCHE), ForSight VISION5, Inc. (Acquired by Allergan), and ForSight VISION6, Inc., including subsidiary FSV6, Ltd, Israel (privately held). Learn about the products identified, the methodology utilized to develop the products, and the path from idea to product to company sale for this incredible portfolio. Join David Cassak as he interviews Dr. Gene de Juan and Angela Macfarlane about the journey and their plans for the future.


David Cassak, The MedTech Strategist


Eugene de Juan, ForSight Labs


Angela Macfarlane, ForSight Labs

2:20 – 2:40 p.m.


2:40 – 3:40 p.m.

Breakout Session 4

IPOs and Mergers Click here to play audio
M&A activity in the Medtech sector continues at a solid pace. Medtech consolidators have been busy exercising buyout options they put in place in prior years, while a growing number of Medtech companies have completed mergers on the eve of regulatory approval or soon after launching their products in the United States. On the IPO front, a substantial number of companies have filed for IPOs and an impressive number of companies have completed IPOs during the last few years. For Medtech companies with growing sales, it seems as though the window for IPOs is continuing. Against this backdrop, our panel will explore recent M&A and IPO transactions with the goal of understanding what a company needs to have in place to successfully complete these transactions.


Phil Oettinger, Wilson Sonsini Goodrich & Rosati


Jed Cohen, Leerink Partners


Rob Faulkner, Redmile Group


Kevin King, iRhythm Technologies, Inc.


Arthur Taylor, Transcend Medical, Inc.

Collaborations Between Japan and Silicon Valley Click here to play audio
Momentum has been growing between Japanese companies and Medtech companies as investments, mergers, and acquisitions have increased and promise to continue. Initially it was primarily development projects and Venture Capital investments. More recently Corporate VC investments and acquisitions has been added as well as other forms of collaboration. This represents a major opportunity for start-ups to seek investments from and partnerships with Japanese businesses. Come learn about the ways in which Japan and start-ups are collaborating to finance and develop advanced medical technologies.


Jack Moorman, US-Japan MedTech Frontiers (USJMF)


Kenichi "Ken" Hata, Terumo Corporation


Masazumi "Masa" Ishii, AZCA Inc.


Yuichiro Morimoto, Enplas Corporation


Richard "Rick" Packer, Asahi Kasei Corporation/ZOLL Medical Corporation

Strategic Positioning to Avoid or Minimize the Risk of Earn-out Disputes Click here to play audio
Merger deals often involve the negotiation of financially significant earn-out milestones. It is not uncommon for these negotiated terms to lead to friction after the acquisition, particularly when a milestone is not met. For example, disputes can arise regarding whether the acquirer exercised commercially reasonable efforts in achieving one or more milestones. Hear from Chris Letang, Managing Director of SRS Acquiom's Professional Services team. Chris and his team work to resolve disputes about contingent consideration owed in M&A transactions, among other things. He will discuss how and when these disputes most often arise and the potentially significant ramifications to the remaining shareholder group. Also hear from William P. Farrell Jr., a founder, managing director and general counsel of Longford Capital, a leading private investment company who can provide targeted funding in the event such a dispute does arise so that the shareholders need not bear all of the risk. The panel will be moderated by Vera Elson, a seasoned trial attorney and litigation partner at WSGR.


Vera Elson, Wilson Sonsini Goodrich & Rosati


William Farrell, Jr., Longford Capital Management, LP


Christopher Letang, SRS Acquiom

3:40 – 4:00 p.m.


4:00– 5:00 p.m.

MedTech Innovator 2017 Click here to play audio
Four early-stage Medtech companies selected from nearly 600 applications will present their pitches to a panel of judges. The judges will evaluate the presentations and provide feedback to each of the companies. Ultimately, the audience votes for the winner of the $25K MedTech Innovator 2017 Value Award. The winner will also be profiled in an upcoming issue of The MedTech Strategist.


Paul Grand, MedTech Innovator


Amy Len Kobe, Baxter Ventures


Jennifer Kozak, Johnson & Johnson


Praveen Raja, Amgen


Jenell Paul-Robinson, MedTech Innovator

5:00 – 6:30 p.m.

Venture Capital Uncorked: Wine Tasting Reception
Join Wilson Sonsini Goodrich & Rosati for a wine tasting session following the conference. We will be sampling wines from various wineries, with venture capitalists serving as your sommeliers for the event. This is your chance to try some great wine and learn a little bit more about what each of our local venture firms are looking for in their next deal. It's a great pairing — wine with a venture capital twist.